Susan Moench, PhD, PA-C

A single-institution, retrospective study determined that having a tangible item improved patient adherence to radiotherapy on-treatment clinic visits.

Patients were evaluated according to both mRECIST and iRECIST for those with malignant pleural mesothelioma and those receiving immunotherapy, respectively.

Nurses working in primary care settings are well-situated to identify and educate patients at high risk of lung cancer who are eligible to undergo LDCT screening.

Optimal treatment of patients with EGFR-TKI–associated ILD is based on rapid diagnosis and the timely implementation of specific interventions.

Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.

Palliative care and end-of-life needs were not addressed for approximately 40% of simulated patients who would have been eligible for this approach.

There are few clinical trials examining immune checkpoint inhibitor therapy in advanced NSCLC that enroll a high percentage of Asian patients.

Autologous activated killer T cells and dendritic cells from regional lymph nodes were infused with or without chemotherapy in the adjuvant setting.

IBM Watson Health’s Clinical Trials Matching (CTM) is an artificial intelligence system that can increase the efficiency of patient screening and recruitment into clinical trials.

There are few observational studies examining patients with aNSCLC who have been treated with immune checkpoint inhibitor therapy.

Treatment-related adverse effects of the sintilimab-anlotinib combination regimen included hand-foot syndrome and hyponatremia.